Loading...
Loading...
Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences
EW and increases its price target on shares from $90 to $118.
Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)."
Edwards Lifescience closed at $104.44 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in